LSV Asset Management
VRTX icon

LSV Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LSV Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,051
Closed -$1.14M – 899
2022
Q2 		$1.14M Sell
4,051
-700
-15% -$187K ﹤0.01% 661
2022
Q1 		$1.24M Buy
4,751
+3,200
+206% +$759K ﹤0.01% 684
2021
Q4 		$341K Buy
+1,551
New +$302K ﹤0.01% 795
2013
Q4 		– Sell
-950
Closed -$72K – 952
2013
Q3 		$72K Buy
+950
New +$75.6K ﹤0.01% 938

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LSV Asset Management's VRTX Position: Q3 2022 in Review

LSV Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 4,051 shares — an estimated $1.14M sold.

LSV Asset Management first reported a position in VRTX in Q3 2013 and held it in 4 quarters. The position peaked at $1.24M in Q1 2022. 1,127 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • LSV Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • LSV Asset Management sold 4,051 Vertex Pharmaceuticals shares in Q3 2022, an estimated $1.14M.
  • LSV Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • LSV Asset Management's Vertex Pharmaceuticals position peaked at $1.24M in Q1 2022.
  • 1,127 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on LSV Asset Management's 13F filing for Q3 2022, filed 4 Nov 2022.